Page 1

BioSyent BioSyent Releases Financial Results for Q2 and H1 2026 -- MISSISSAUGA , Ontario , Aug. 20 , 2026 BioSyent Inc. ( " BioSyent " , TSX Venture : RX ) released today its consolidated financial results for the three months ( Q2 ) , six months ( H1 ) , and trailing twelve months ( TTM ) ended June 30 , 2026. Key highlights include : % Change % Change % Change TTM VS. ( CAD ) Q2 2026 VS. H1 2026 Q2 2025 VS. Jun 30 , TTM H1 2025 2026 Jun 30 , 2025 Pharmaceutical Sales 11,110,365 Oral Health Sales 8,224,402 Insecticide Sales 537,996 + 14 % 21,913,472 n / a 11,209,375 + 32 % 658,098 + 7 % 42,325,508 + 11 % n / a 11,209,375 n / a -5 % 2,139,789 + 51 % Total Company Sales 19,872,763 + 95 % 33,780,945 + 60 % 55,674,672 + 41 % EBITDA¹ 4,976,253 + 80 % 8,615,339 + 45 % 14,776,299 + 34 % Net Income After Taxes ( NIAT ) 2,849,437 + 41 % 5,194,256 + 20 % 9,868,384 + 19 % Fully Diluted EPS 0.25 + 39 % 0.45 + 19 % 0.85 + 18 % • Q2 2026 was first full quarter of financial results contributed by Oral Health segment following March 1 , 2026 acquisition of Oral Science Inc .: о $ 8.2 million sales ° $ 1.5 million EBITDA¹ ° $ 1.1 million NIAT ( before $ 0.75 million amortization expense on acquired intangible assets ) • Q2 2026 consolidated EBITDA¹ margin : 25 % to sales ( 26 % to sales - adjusted for one - time acquisition costs ) • H1 2026 consolidated EBITDA¹ margin : 26 % to sales ( 27 % to sales - adjusted for one - time acquisition costs ) • Return on Average Equity for the trailing twelve months ( ' TTM ' ) ended June 30 , 2026 was 24 % , increasing from 23 % for TTM June 30 , 2025 • During H1 2026 , repurchased and cancelled a total of 218,500 common shares under a Normal Course Issuer Bid ( NCIB ) • Paid quarterly cash dividends of $ 0.055 per common share on March 13 , 2026 and June 15 , 2026 • Declared subsequent cash dividend of $ 0.055 per common share to be paid on September 15 , 2026 " We are very pleased with the first full quarter of operating results delivered by our new Oral Health segment in Q2 2026 , " commented Mr. René Goehrum , President and CEO of BioSyent . " The added sales and profit from the Oral Health segment when combined with continued growth in our existing Pharmaceutical segment , both in Canada and internationally , resulted in total Company quarterly sales and EBITDA¹ growth of 95 % and 80 % , respectively , over the comparative quarter . With H1 2026 operating cash flows from the Oral Health segment of $ 1.3 million since the March 1st acquisition date combined with $ 3.9 million in H1 2026 operating cash flows from our Pharmaceutical and Insecticide businesses , we continued to invest in growing all of our businesses in H1 2026 in addition to paying down our short term acquisition debt , buying back shares under our Normal Course Issuer Bid , and paying regular quarterly dividends . Though we continue to face economic uncertainty in Canada and geopolitical instability internationally , we are well - positioned with a strong balance sheet and more diversified product portfolio , to continue to deliver on our strategic priorities of profitable growth , portfolio diversification and long - term value creation for our shareholders . " The CEO's presentation on the Q2 2026 Results is available at the following link : www.biosyent.com/investors/ The Company's Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three and six months ended June 30 , 2026 and 2025 will be posted on www.sedarplus.ca on August 20 , 2026 . The Company further announces that its Board of Directors has approved a grant of 590 Restricted Share Units ( " RSUs " ) to certain employees of the Company pursuant to the Company's RSU Plan . These RSUs will fully vest within three years on the third anniversary of the applicable grant date . For a direct market quote for the TSX Venture Exchange and other Company financial information , please visit www.tmxmoney.com . About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol " RX " , BioSyent is a profitable growth - oriented specialty